enteric-nervous-system-expanded

Enteric Nervous System

Introduction

The enteric nervous system (ENS) is often called the "second brain" due to its complex network of neurons embedded in the gastrointestinal tract wall. With approximately 100 million neurons—roughly the same number as in the spinal cord—the ENS controls gut motility, secretion, blood flow, and immune functions autonomously, though it communicates extensively with the central nervous system (CNS) via the vagus nerve and sympathetic pathways. [@furnish2019]

Enteric Nervous System

Introduction

The enteric nervous system (ENS) is often called the "second brain" due to its complex network of neurons embedded in the gastrointestinal tract wall. With approximately 100 million neurons—roughly the same number as in the spinal cord—the ENS controls gut motility, secretion, blood flow, and immune functions autonomously, though it communicates extensively with the central nervous system (CNS) via the vagus nerve and sympathetic pathways. [@furnish2019]

In recent years, the ENS has emerged as a critical player in neurodegenerative diseases, particularly Parkinson's disease (PD), where the gut-brain axis hypothesis proposes that pathology originates in the gastrointestinal tract and propagates retrogradely to the brain via the vagus nerve. This theory has profound implications for understanding disease initiation, early detection, and therapeutic intervention. [@braak2003]

Anatomy and Cellular Organization

Structural Organization

The ENS is organized into two major ganglionated plexuses:

• Myenteric plexus (Auerbach's plexus): Located between the longitudinal and circular muscle layers; primarily controls gut motility and peristalsis
• Submucosal plexus (Meissner's plexus): Located in the submucosa; regulates intestinal secretion, absorption, and blood flow

Enteric Glia

Enteric glial cells (EGCs) are essential for ENS function, analogous to astrocytes in the CNS:

• Morphology: star-shaped cells ensheathing neuronal soma and processes
• Markers: GFAP, S100B, Sox10
• Functions:
• Metabolic support for neurons (lactate shuttling)
• Maintenance of the intestinal epithelial barrier
• Modulation of immune responses
• Regulation of neurotransmission
• Support of neuronal survival during stress

Interstitial Cells of Cajal (ICCs)

ICCs serve as pacemakers in the gastrointestinal tract:

• Location: Within muscle layers, particularly the myenteric plexus region
• Function: Generate slow-wave potentials that coordinate rhythmic gut contractions
• Markers: c-KIT (CD117), ANO1
• Pathology in PD: ICC loss correlates with gastroparesis in PD patients

Enteroendocrine Cells

Enteroendocrine cells (EECs) represent the largest endocrine organ in the body:

• Types: CCK cells, G cells, EC cells (serotonin), L cells (GLP-1, PYY)
• Function: Sense nutrients, release hormones regulating satiety, glucose homeostasis
• Connection to neurodegeneration: EECs express alpha-synuclein and may serve as reservoirs for pathology spread

Molecular Markers and Neurochemistry

Neurotransmitter Systems

The ENS employs multiple neurotransmitter systems:

| Neurotransmitter | Function | Neuron Population |
|-----------------|----------|-------------------|
| Acetylcholine | Excitatory motor | Cholinergic neurons |
| Nitric oxide | Inhibitory motor | Nitrergic neurons |
| VIP | Secretion, relaxation | VIPergic neurons |
| Substance P | Excitatory sensory | Tachykinergic neurons |
| Serotonin | Motility modulation | Serotonergic neurons |
| CGRP | Sensory signaling | CGRP neurons |
| ATP | Fast excitatory | Purinergic neurons |

Neuropeptides

Beyond classical neurotransmitters, the ENS expresses numerous neuropeptides:

• Galanin: Co-released with norepinephrine; modulates enteric motility
• Neuropeptide Y (NPY): Inhibits secretion and motility
• Somatostatin: Inhibits release of other peptides
• Bombesin: Regulates satiety and gastric acid secretion

Role in Parkinson's Disease

The Braak Hypothesis

In 2003, Braak and colleagues proposed that idiopathic Parkinson's disease begins with an unknown pathogen entering the body through the nasal cavity or gastrointestinal tract, triggering alpha-synuclein pathology in vulnerable neuronal populations. [@braak2003] According to this model:

This staged progression implies that the ENS may harbor the initiating pathological events years before motor symptoms appear. [@chandra2019]

Alpha-Synuclein in the ENS

Phosphorylated alpha-synuclein (pSer129):

• Pathological hallmark of PD in the ENS
• Detected in 50-80% of early PD patients via gastrointestinal biopsy
• Found in individuals with idiopathic REM sleep behavior disorder (iRBD), a PD prodrome

• Proximal GI tract (esophagus, stomach) affected before distal (colon)
• Myenteric plexus more vulnerable than submucosal plexus
• Specific neuronal subtypes show differential vulnerability

Evidence from Studies

Gastrointestinal alpha-synuclein in premotor PD:

• phosphorylated alpha-synuclein (pSer129) deposits detected in ENS neurons of individuals with idiopathic REM sleep behavior disorder (iRBD), a PD prodrome
• Studies show 50-80% of early PD patients have detectable ENS pathology at biopsy
• The pattern of involvement follows a proximal-to-distal gradient, with the esophagus and stomach affected before the colon

• Constipation precedes motor PD by 10-20 years in most patients
• Other GI symptoms including dysphagia, nausea, and gastroparesis are common in prodromal stages
• PMID: 20887898(https://pubmed.ncbi.nlm.nih.gov/20887898/)

Mechanisms of Propagation

Several hypotheses explain how alpha-synuclein pathology might spread from ENS to CNS: [@borghammer2021]

Supporting Evidence

Epidemiological studies:

• PMID: 19145172(https://pubmed.ncbi.nlm.nih.gov/19145172/)
• PMID: 21810660(https://pubmed.ncbi.nlm.nih.gov/21810660/)
• Vagotomy associated with reduced PD risk in some cohort studies

• PMID: 25925842(https://pubmed.ncbi.nlm.nih.gov/25925842/)
• Altered vagal tone in early PD measured by heart rate variability

• PMID: 31194225(https://pubmed.ncbi.nlm.nih.gov/31194225/)
• Rodent studies demonstrate vagal propagation of alpha-synuclein

Gut Microbiome and Neuroinflammation

Dysbiosis in Parkinson's Disease

Multiple studies have documented altered gut microbiota in PD patients: [@sampson2016]

• Reduced microbial diversity
• Increased Prevotellaceae, Enterobacteriaceae
• Decreased Bacteroidetes, Lachnospiraceae
• Elevated intestinal permeability ("leaky gut")

Microbial Metabolites and Neuroinflammation

Gut bacteria produce metabolites that influence CNS function:

• Short-chain fatty acids (SCFAs): Butyrate, propionate; reduced in PD; modulate microglial activation
• LPS from gram-negative bacteria: Triggers neuroinflammation when translocated across leaky gut
• Trimethylamine N-oxide (TMAO): Elevated in PD; associated with mitochondrial dysfunction

Evidence from Animal Models

Germ-free mice colonized with PD patient fecal microbiota show: [@caputi2022]

• Enhanced motor deficits
• Increased alpha-synuclein aggregation in brain
• Reduced microglial ramification
• Elevated intestinal inflammation

Other Neurodegenerative Diseases

Alzheimer's Disease

While less studied than in PD, ENS involvement in AD includes:

• PMID: 32581342(https://pubmed.ncbi.nlm.nih.gov/32581342/)
• Amyloid-beta deposits detected in ENS neurons
• Altered gut motility in AD patients
• Gut microbiome changes correlate with cognitive decline

Multiple System Atrophy (MSA)

MSA shows distinct gastrointestinal involvement:

• PMID: 31965087(https://pubmed.ncbi.nlm.nih.gov/31965087/)
• Severe autonomic dysfunction including gastrointestinal failure
• Different pattern of ENS pathology compared to PD

Amyotrophic Lateral SALS (ALS)

Gastrointestinal dysfunction in ALS:

• PMID: 30896515(https://pubmed.ncbi.nlm.nih.gov/30896515/)
• Malnutrition and weight loss major concerns
• Altered gut microbiome in ALS mouse models
• Potential therapeutic implications

Clinical Implications

Diagnostic Potential

Gastrointestinal biopsies:

• Rectal or colonic biopsies can detect phosphorylated alpha-synuclein
• Sensitivity for early PD: ~70-80%
• May enable premotor diagnosis in at-risk individuals

• Microbial signatures associated with PD diagnosis
• Potential for non-invasive screening

• Volatile organic compounds (VOCs) as biomarkers
• Fecal calprotectin for gut inflammation

Therapeutic Approaches

Targeting the gut:

• Probiotics: Lactic acid bacteria trials show improvement in motor symptoms and constipation
• Fecal microbiota transplantation (FMT): Investigational; case reports suggest benefit
• Dietary interventions: Mediterranean diet, prebiotic fiber supplementation

• Vagotomy: Historical studies suggest reduced PD risk after truncal vagotomy
• Blood-brain barrier modulation: Targeting transport mechanisms

• PMID: 33132765(https://pubmed.ncbi.nlm.nih.gov/33132765/)
• PMID: 32877967(https://pubmed.ncbi.nlm.nih.gov/32877967/)
• PMID: 31671720(https://pubmed.ncbi.nlm.nih.gov/31671720/)
• PMID: 30080998(https://pubmed.ncbi.nlm.nih.gov/30080998/)

ENS in Aging and Cellular Senescence

Age-Related Changes in the ENS

The ENS undergoes significant changes with aging:

• PMID: 28730439(https://pubmed.ncbi.nlm.nih.gov/28730439/)
• Declining neuronal numbers
• Glial reactivity
• Reduced mitochondrial function
• Altered neurotransmitter production

Cellular Senescence

Senescent enteric neurons exhibit:

• PMID: 30224658(https://pubmed.ncbi.nlm.nih.gov/30224658/)
• SA-β-gal positivity
• SASP (Senescence-Associated Secretory Phenotype) production
• Pro-inflammatory cytokine release
• Impaired mitochondrial biogenesis

Enteric Neuronal Vulnerability in Neurodegeneration

Selective Vulnerability

Not all ENS neurons are equally vulnerable to pathological insults:

• Most vulnerable: cholinergic motor neurons, nitrergic inhibitory neurons
• More resistant: serotonergic neurons, CGRP sensory neurons
• Molecular basis: Differential expression of proteins involved in protein homeostasis, mitochondrial function, and oxidative stress response

Mechanisms of Vulnerability

Future Directions and Research Gaps

Unresolved Questions

Emerging Research Areas

• Single-cell transcriptomics of enteric neurons in PD
• Organoid models of the ENS
• Targeting gut inflammation as disease-modifying therapy
• Development of gut-restricted neuroprotective agents

Summary

The enteric nervous system, once viewed primarily as an autonomous regulator of gastrointestinal function, now occupies a central position in neurodegenerative disease research. The gut-brain axis provides a compelling framework for understanding how alpha-synuclein pathology might initiate in the ENS and propagate to the CNS, potentially decades before clinical diagnosis. This paradigm shift opens new avenues for early detection, disease-modifying therapies, and ultimately, prevention of Parkinson's disease and related alpha-synucleinopathies.

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein Propagation](/mechanisms/alpha-synuclein-propagation)
• [Gut-Brain Axis in Neurodegeneration](/mechanisms/gut-brain-axis)
• [Vagus Nerve](/cell-types/vagus-nerve-neurons)

References